ArticleAnnals of medicine2026

Frequency-adjusted daratumumab-based regimen versus bortezomib/dexamethasone in newly diagnosed AL amyloidosis: a matched-cohort study.

Wanting Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.